Overall Status

Active, not recruiting (1)

Sign in for free

Phase

phase 2 (1)

Sponsor

National Cancer Institute (NCI) (1)

Collaborator

Intervention

nivolumab (1)

varlilumab (1)

Study Documents

Intervention Type

biological (1)

drug (1)

Funder Type

NIH (1)

Study Type

Interventional (1)

recurrent lymphomatoid granulomatosis

Showing 1 - 1 of 1

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

ALK-Positive Large B-Cell Lymphoma, Burkitt-Like Lymphoma With 11q Aberration, DLBCL Activated B-Cell Type Trial in United

Active, not recruiting

ALK-Positive Large B-Cell Lymphoma
+34 more

Nivolumab
Varlilumab

Phoenix, Arizona
+32 more

Jan 3, 2023